Epidemic keratoconjunctivitis Market

Key Highlights

• Epidemic Keratoconjunctivitis (EKC) is a highly contagious viral conjunctivitis. It is caused by a group of viruses known as adenoviruses that, in addition to ocular surface infections, are responsible for causing infectious diseases of the gastrointestinal tract and respiratory system illnesses such as the common cold virus.
• In the year 2023, the total incident cases of Epidemic Keratoconjunctivitis were approximately 1.8 million in the 7MM.
• Among the 7MM, Japan accounts for more than 50% of total incident cases of Epidemic Keratoconjuctivitis.
• The United States, in 2023, accounted for around 40% of cases of viral conjunctivitis, which will probably rise by the year 2034.
• Among EU4 countries and the UK, the highest number of cases of Epidemic Keratoconjunctivitis were in Germany, i.e., ~86,000 cases in the year 2023, which are estimated to decrease by the year 2034.
• Among EU4 and the UK, the lowest number of cases of Epidemic Keratoconjunctivitis were in Spain, i.e., ~48,000 cases in the year 2023, which are estimated to increase the year 2034.

DelveInsight's “Epidemic Keratoconjunctivitis (EKC)–Epidemiology Forecast – 2034” report delivers an in-depth understanding of Epidemic Keratoconjunctivitis (EKC), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020–2034

Epidemic Keratoconjunctivitis (EKC) Understanding and Treatment Algorithm

Epidemic Keratoconjunctivitis (EKC) Overview and Diagnosis

Epidemic keratoconjunctivitis (EKC) is a highly contagious adenoviral infection that causes severe inflammation of the conjunctiva and cornea. Adenovirus serotypes 8, 19, and 37 are commonly found to be associated with Epidemic Keratoconjuctivitis and are considered to be a more critical form of adenoviral keratoconjunctivitis because of the adverse consequences it may have on visual acuity. The patients suffering from this condition often show symptoms such as redness (“pink eye”), swelling of the eyelids, and many more. Epidemic keratoconjunctivitis commonly begins with flu-like symptoms such as fever, muscular aches, malaise, and swollen lymph nodes before ocular symptoms appear. When eye problems do appear, they usually do so in stages. The early acute phase, which lasts seven to ten days after the onset of symptoms, is marked by conjunctival inflammation with or without corneal involvement.

The diagnosis of Epidemic keratoconjunctivitis is based mainly on history and clinical picture, but cell culture in combination with immunofluorescence staining (CC-IFA) is a good tool for diagnosis. As well as Polymerase Chain Reaction (PCR) is very specific in the detection of adenovirus antigen. These methods are the most accurate way to confirm the diagnosis.

Further details related to country-based variations in diagnosis are provided in the report…

Epidemic Keratoconjunctivitis (EKC) Epidemiology

The Epidemic Keratoconjunctivitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total Incident cases of Viral conjunctivitis, total Adenovirus D-specific Incident Cases, total Incident Cases of Epidemic keratoconjunctivitis, total diagnosed Incident Cases of Epidemic keratoconjunctivitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. The total cases of Epidemic Keratoconjunctivitis in the 7MM comprised approximately 1,821,000 cases in 2023 and are projected to decrease during the forecast period.

• In 2023, the total incident cases of viral conjunctivitis in the United States were around 2.8 million, which are anticipated to increase by 2034.
• In 2023, the total adenovirus D-specific incident cases in the United States were approximately 1.3 million, which are anticipated to increase by 2034.
• Among 7MM, Japan accounted for the highest number of Incident cases of Epidemic keratoconjunctivitis i.e. around 1 million in 2023.
• In EU4 and the UK, there were around 326,000 incident cases of Epidemic keratoconjunctivitis, out of which the highest number was recorded in Germany and lowest in Spain.
• In 2023, the total incident cases of Epidemic keratoconjunctivitis in the United States were around 510,000, which are anticipated to decrease by 2034.

Total Incident Cases of Epidemic keratoconjunctivitis in the 7MM (2023)

KOL Views

To keep up with the real-world scenario, we take opinions from Key Industry leaders working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Epidemiology, including Medical/scientific Writers, Professors, and others.

DelveInsight’s analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 18+ KOLs in the 7MM. Centers such as University Medical Centre Tübingen, Anglia Ruskin University, Johns Hopkins Wilmer Eye Institute etc. were contacted. Their opinion helps understand and validate current and future epidemiology patterns.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Epidemic Keratoconjunctivitis , explaining its causes, signs and symptoms, diagnosis, pathogenesis, and Epidemiology.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression.
• A detailed review of the Epidemic Keratoconjunctivitis (EKC) Epidemiology, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM patient pool.

Epidemic Keratoconjunctivitis (EKC) Report Insights

Patient Population

• Country-wise Epidemiolohgy Distribution

Epidemic Keratoconjunctivitis (EKC) Report Key Strengths

• Eleven Years Forecast
• The 7MM Coverage
• Epidemic Keratoconjunctivitis (EKC) Epidemiology Segmentation

Epidemic Keratoconjunctivitis (EKC) Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of Epidemic Keratoconjunctivitis (EKC)? What will be the growth opportunities across the 7MM with respect to the patient population of Epidemic Keratoconjunctivitis (EKC)?
• What is the historical and forecasted Epidemic Keratoconjunctivitis (EKC) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What is the biomarker testing rate among this patient pool?
• Why do only limited patients appear with symptoms? Why is the current year diagnosis rate not high?

Reasons to buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.